股东方面，截至2025年3月31日，稳健医疗股东户数21410户，较上次减少2643户，户均持股市值35.28 万元，户均持股数量2.76万股。 7月4日，稳健医疗今日收盘40.2元，下跌2.43%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到30.74倍，总市值234.10亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8稳健医疗30.7433.662.05234.10亿行业平均 38.9646.134.06105.57亿行业中值43.1140.682.5868.23亿1依依股份17.7118.692.1340.20亿2科思股份 18.4112.792.6371.92亿3珀莱雅19.5820.685.59320.96亿4敷尔佳21.6919.712.27130.34亿5豪悦护理 22.3022.582.5887.49亿6诺邦股份27.6630.552.0329.09亿7爱美客27.8726.686.34522.33亿9百亚股份 36.6140.187.31115.58亿10力合科创37.0839.411.3396.73亿11润本股份39.5340.685.75122.11亿12 ...

资金流向方面，6月26日，稳健医疗主力资金净流出209.55万元，近5日总体呈流出状态，5日共流出 2480.19万元。 6月26日，稳健医疗今日收盘39.82元，下跌1.17%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到30.45倍，总市值231.88亿元。 从行业市盈率排名来看，公司所处的美容护理行业市盈率平均39.12倍，行业中值42.46倍，稳健医疗排 名第13位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8稳健医疗30.4533.352.03231.88亿行业平均 39.1246.454.08105.69亿行业中值42.4639.882.5867.61亿1依依股份16.7117.632.0137.92亿2科思股份 18.2512.682.6171.31亿3珀莱雅19.9221.045.68326.51亿4敷尔佳21.7419.752.27130.60亿5豪悦护理 22.0522.332.5586.52亿6爱美客27.8026.616.32521.00亿7诺邦股份28.9331.952.1330.43亿9百亚股份 36.3539.887.26114.73亿10力合科创3 ...

Company Overview - Company name is稳健医疗, which closed at 50.47 yuan on June 10, with a 2.25% increase, resulting in a rolling PE ratio of 38.59 times and a total market value of 29.39 billion yuan [1] - The main business of the company includes research, production, and sales of cotton-based products, with key products being high-end wound dressings, traditional wound care products, surgical consumables, infection protection products, and personal health products [1] Financial Performance - For Q1 2025, the company reported revenue of 2.605 billion yuan, a year-on-year increase of 36.47%, and a net profit of 249 million yuan, also up 36.26%, with a gross profit margin of 48.46% [2] - The company's PE ratio is 38.59 (TTM) and 42.26 (static), with a price-to-book ratio of 2.58 [2] Industry Comparison - The average PE ratio for the beauty and personal care industry is 44.04, with a median of 49.17, placing the company at 14th in the industry ranking [1][2] - The total market value of the industry averages 115.99 billion yuan, with the median at 74.78 billion yuan [2] Market Position - The company has consistently ranked among the top three exporters of medical dressings in China for several years [1] - The "winner" brand has entered over 2,000 hospitals and nearly 40,000 pharmacies in China, with a significant presence in major chains [1]

21世纪经济报道记者柳宁馨 杭州报道 杭州市经信局二级巡视员杨荣欣表示，此次对接会的举办，将为企业搭建起一个重要的交流合作平台， 通过与电商平台开展深度产销对接，实现平台赋能、资源聚合，为企业打通堵点、链接商机，在变局中 开创新局。对于外贸企业而言，"内外贸一体化"是应对挑战、促进长远发展的重要路径。 余杭区经信局党委书记、局长徐春表示，当前消费品类企业面临订单减少、成本上升、市场竞争加剧等 重重挑战。为此，余杭区深入调研企业痛点难点，掌握到企业想要打破内外贸壁垒，开拓更广阔的市场 的诉求，主动对接杭州市经信局筹备本次对接会。同时，余杭区还致力于为企业提供丰富的应用场景。 当前，全球经济形势复杂多变，单边主义、贸易壁垒不断冲击国际市场秩序，给制造业企业带来了前所 未有的挑战。 5月20日，由杭州市经信局主办，余杭区经信局承办的杭州市消费品类企业"内外贸一体化"对接会（余 杭站）在阿里巴巴园区顺利举行，西湖、余杭、富阳和临安区42家企业50余人参会。活动旨在帮助企业 应对复杂多变的国际环境，稳增长、拓市场。 （对接会现场，图片由杭州市经信局提供） 淘天集团、1688、全球速卖通、阿里国际站、Lazada华东、钉 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company, Steady Medical, within the healthcare and personal care industry [1][2] - As of May 19, the company's stock closed at 50.75 yuan, with a PE ratio of 38.81 times and a total market capitalization of 29.553 billion yuan [1] - The average PE ratio for the beauty and personal care industry is 46.41 times, with a median of 49.27 times, placing Steady Medical at the 14th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, the company reported a revenue of 2.605 billion yuan, representing a year-on-year increase of 36.47%, and a net profit of 249 million yuan, also up by 36.26% [2] - The company's gross profit margin stands at 48.46% [2] - Steady Medical specializes in the research, production, and sales of cotton-based products across various sectors, including medical, personal care, and home care [1]

Group 1 - The core viewpoint of the news highlights the performance and market position of the company, Steady Medical, in the healthcare industry, particularly in the medical dressing sector [1][2]. - As of May 9, the company's stock closed at 51.45 yuan, reflecting a 3.31% increase, with a rolling price-to-earnings (PE) ratio of 39.34 times and a total market capitalization of 29.961 billion yuan [1]. - The average PE ratio for the beauty and healthcare industry is 41.70 times, with a median of 45.39 times, placing Steady Medical at the 14th position within the industry [1][3]. Group 2 - Steady Medical specializes in the research, production, and sales of cotton-based products across various sectors, including medical, personal care, and home care [2]. - The company's main products include high-end wound dressings, traditional wound care products, infection control products, and various cotton-based personal care items [2]. - According to recent performance data, for the first quarter of 2025, the company reported revenue of 2.605 billion yuan, a year-on-year increase of 36.47%, and a net profit of 249 million yuan, also up by 36.26%, with a gross profit margin of 48.46% [2].

点击注册小程序 2 4 年 医用耗材收入占总收入的比重为 43.5%，收入同比增长1.1%，其中24年9月收购的美国医用耗材公 司GRI贡献收入2.9亿，剔除后收入同比下滑6.4%；毛利率同比下降3.9PCT至36.5%（感染防护产品毛利率 同比下降23.5PCT至21.2%，剔除后其他品类毛利率下降1.1PCT），营业利润率同比下降1.1PCT至7.6%； 25Q1收入同比增长46.3%，剔除GRI并表影响同比增长10.5%。 1）分渠道来看： 2 4 年 海外渠道收入占比为 54.4%，收入同比增长37.7%； 25Q1国外收入同比增长 84.1%，C端业务（国内药店、电商）收入同比增长超40%。 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 24年收入/归母净利润同比+9.7%/+ ...

2025 年 5 月 7 日 公司研究 Q1 业绩表现亮眼，医疗和消费品板块协同发力 ——稳健医疗（300888.SZ）2024 年年报及 2025 年一季报点评 增持（维持） 当前价：52.22 元 作者 分析师：姜浩 执业证书编号：S0930522010001 021-52523680 jianghao@ebscn.com 分析师：孙未未 执业证书编号：S0930517080001 021-52523672 sunww@ebscn.com 分析师：朱洁宇 执业证书编号：S0930523070004 021-52523842 zhujieyu@ebscn.com | 市场数据 | | | --- | --- | | 总股本(亿股) | 5.82 | | 总市值(亿元)： | 304.09 | | 一年最低/最高(元)： | 22.99/54.80 | | 近 3 月换手率： | 61.74% | 股价相对走势 -30% -12% 6% 24% 42% 04/24 07/24 10/24 01/25 稳健医疗 沪深300 | 收益表现 | | | | | --- | --- | --- | --- | | % ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 60.06 RMB [8][9]. Core Views - The company reported a strong start in Q1 2025, with revenue growth accelerating. For 2024, the company achieved revenue of 8.98 billion RMB, a year-on-year increase of 9.7%, and a net profit of 700 million RMB, up 19.8% year-on-year. The Q1 2025 revenue was 2.61 billion RMB, reflecting a year-on-year growth of 36.5% [1][5]. - The growth in revenue and profit is attributed to the acceleration in consumer goods and the consolidation of GRI in the medical business. The consumer goods segment is showing improvement, and the medical segment has effectively absorbed high base pressures [1][2]. Summary by Sections Consumer Goods - In 2024 and Q1 2025, the health lifestyle consumer goods segment achieved revenues of 4.99 billion RMB and 1.34 billion RMB, respectively, with year-on-year growth of 17.1% and 28.8%. Key product categories such as cotton soft towels and sanitary napkins saw significant growth, with revenues increasing by 31% and 18% respectively in 2024 [2]. Medical Supplies - The medical supplies segment reported revenues of 3.91 billion RMB in 2024 and 1.25 billion RMB in Q1 2025, with year-on-year growth of 1.1% and 46.3%. The infection protection products faced a high base pressure, with a revenue decline of 61.2% in 2024, but this pressure is gradually being absorbed [3]. Financial Metrics - The gross margin for 2024 decreased by 1.7 percentage points to 47.3%, primarily due to rising raw material costs. The expense ratio also decreased by 1.7 percentage points to 35.5%, benefiting from revenue growth diluting expenses [4]. - The company has adjusted its revenue forecasts for 2025-2026 upwards, with expected net profits of 1.06 billion RMB, 1.30 billion RMB, and 1.59 billion RMB for 2025, 2026, and 2027 respectively. The target price is based on a 33 times PE ratio for 2025 [5][9].

Investment Rating - The investment rating for the company is "Buy" with a target price of RMB 60.06 [8][9]. Core Insights - The company reported a revenue of RMB 8.98 billion in 2024, a year-on-year increase of 9.7%, and a net profit of RMB 700 million, up 19.8% year-on-year. The revenue exceeded previous expectations, while profit was slightly below due to an asset impairment loss of approximately RMB 240 million [1]. - In Q1 2025, the company achieved a revenue of RMB 2.61 billion, representing a year-on-year growth of 36.5%, and a net profit of RMB 250 million, also up 36.3% year-on-year. This growth is attributed to accelerated consumer goods sales and the consolidation of GRI in the medical segment [1]. - The company is expected to benefit from a dual growth strategy in consumer and medical sectors, with a strong growth momentum anticipated in 2025 [1]. Summary by Sections Consumer Products - The health and lifestyle consumer products segment generated revenues of RMB 4.99 billion in 2024 and RMB 1.34 billion in Q1 2025, with year-on-year growth rates of 17.1% and 28.8%, respectively. Key product categories such as cotton soft towels and sanitary napkins saw double-digit growth [2]. Medical Supplies - The medical supplies segment reported revenues of RMB 3.91 billion in 2024 and RMB 1.25 billion in Q1 2025, with year-on-year growth of 1.1% and 46.3%, respectively. The high base effect from infection prevention products is gradually being digested, while regular products showed strong growth [3]. Financial Metrics - The gross margin for 2024 decreased by 1.7 percentage points to 47.3%, primarily due to rising raw material costs. The expense ratio also decreased by 1.7 percentage points to 35.5%, benefiting from revenue growth [4]. - The company has adjusted its revenue forecasts for 2025-2026 upwards, with expected net profits of RMB 1.06 billion, RMB 1.30 billion, and RMB 1.59 billion for 2025, 2026, and 2027, respectively. The corresponding EPS is projected to be RMB 1.82, RMB 2.23, and RMB 2.73 [5].